The latest generation of “biobetters” which are engineered to be more effective than branded biologics are hitting the market before biosimilars and could make development of the latter pointless, an expert has said.
Q1 revenues for Thermo Fisher’s Life Sciences Solutions business shot up 384% year-over-year in a quarter that saw the integration of Life Technologies.
The US Food and Drug Administration (FDA) has offered guidance for biologics makers as to when two mAbs (monocolonal antibodies) should be viewed as the same.
Epirus and Zalicus have agreed to merge in order to focus on the development and manufacture of biosimilars.
Aastrom Biosciences will pay Sanofi $6.5m for its cell therapy business in a deal that gives the cash strapped regenerative medicines developer three commercial products.
With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, in-Pharmatechnologist.com brings you an interactive view of what £60bn ($101bn) could get.
RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene silencing drugs.
Hospira has announced US recalls for seven lots of its propofol injection and one lot of 1% Lidocaine HCI Injection due to a glass contamination.
The British Generic Manufacturers Association (BGMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) will launch a forum for the generics industry to discuss manufacturing and quality issues.
MSD has selected Catalent to manufacture two recently approved sublingual pollen extract drugs using its Zydis formulation platform.
Novartis has agreed to acquire GlaxoSmithKline’s oncology pipeline for as much as $16bn, while GSK will acquire Novartis’ vaccine business, excluding the flu vaccines, for as much as $7bn.